RecensMedical

At a glance

RecensMedical filed 26 disclosures in the last 12 months, including 8 5% holder and 2 insider. The most recent key filing was on Jul 31: A major holder's stake fell from 5.36% to 4.52% (open-market sale).

Revenue for 2025 was ₩8.8B, up 41% on 2024. It made an operating loss of ₩10.6B. Debt was 72% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.7B.

The 2025 annual report lists 55 employees with an average tenure of 2.7 years and average pay of ₩54M, #1499 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩52M each on average. It paid no cash dividend for 2025. 김건호 and related parties held 23.12% at year end.

Of 5 recent 5%+ holder reports, 3 raised and 2 cut a stake; the largest stake reported was 21.71% on May 22.

From the 2025 annual report

Staff: 55 (42 men, 13 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩3B. Directors and auditors: 5, paid ₩312M in total.

No cash dividend was paid for 2025.

Largest shareholder

김건호 holds 23.07%; with 1 related party the group holds 23.12% of common shares at year end (from 26.91% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports